Grace Lai-Hung Wong, of the Chinese University of Hong Kong, and colleagues conducted a prospective cohort study of 333 patients with bleeding ulcers. After the ulcers healed, patients were divided into two groups: those with prior H. Pylori-negative idiopathic bleeding ulcers and those with H. pylori-positive, nonsteroidal anti-inflammatory drugs-negative bleeding ulcers who received eradication therapy. The groups were followed for seven years or less.
The researchers found that patients in the H. pylori-negative group were significantly more likely to experience recurrent ulcer bleeding compared with the H. pylori-positive group (42.3 versus 11.2 percent). Likewise, the mortality rate was significantly higher in the H. pylori-negative group (87.6 versus 37.3 percent).
"Patients with a history of H. pylori-negative idiopathic bleeding ulcers had a considerable risk of recurrent ulcer bleeding and mortality. Long-term prophylaxis with a gastroprotective agent is probably needed," the authors conclude.
Several of the study authors reported financial relationships with the pharmaceutical industry.
No comments:
Post a Comment